Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract
Abstract Introduction Allogeneic hematopoietic stem cell transplantation (aHSCT) is a curative treatment for hematopoietic malignancies. Graft‐versus‐host disease (GVHD) is a major complication of aHSCT. After transplantation, the balance of immune conditions, such as proinflammatory cytokine level...
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Wiley
2022-09-01
|
| Saila: | Immunity, Inflammation and Disease |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/iid3.688 |